CHROMADEX CORP (CDXC)
US1710774076 - Common Stock
Overall CDXC gets a fundamental rating of 5 out of 10. We evaluated CDXC against 57 industry peers in the Life Sciences Tools & Services industry. CDXC has an excellent financial health rating, but there are some minor concerns on its profitability. CDXC shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year CDXC was profitable.
In the past year CDXC had a positive cash flow from operations.
CDXC had negative earnings in each of the past 5 years.
In the past 5 years CDXC reported 4 times negative operating cash flow.
1.2 Ratios
CDXC has a Return On Assets of 2.63%. This is in the better half of the industry: CDXC outperforms 75.44% of its industry peers.
CDXC's Return On Equity of 4.32% is fine compared to the rest of the industry. CDXC outperforms 73.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.91%, CDXC is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROIC | 0.91% |
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 1.62%, CDXC is doing good in the industry, outperforming 68.42% of the companies in the same industry.
CDXC has a Operating Margin of 0.49%. This is in the better half of the industry: CDXC outperforms 61.40% of its industry peers.
CDXC has a Gross Margin of 61.45%. This is amongst the best in the industry. CDXC outperforms 87.72% of its industry peers.
CDXC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
CDXC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
Compared to 5 years ago, CDXC has more shares outstanding
The debt/assets ratio for CDXC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.30 indicates that CDXC is not in any danger for bankruptcy at the moment.
CDXC has a better Altman-Z score (9.30) than 91.23% of its industry peers.
CDXC has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
CDXC has a Debt to FCF ratio of 0.00. This is amongst the best in the industry. CDXC outperforms 94.74% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CDXC is not too dependend on debt financing.
CDXC has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. CDXC outperforms 80.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 9.3 |
ROIC/WACC0.08
WACC11.34%
2.3 Liquidity
A Current Ratio of 2.95 indicates that CDXC has no problem at all paying its short term obligations.
CDXC's Current ratio of 2.95 is in line compared to the rest of the industry. CDXC outperforms 52.63% of its industry peers.
A Quick Ratio of 2.35 indicates that CDXC has no problem at all paying its short term obligations.
CDXC has a Quick ratio (2.35) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 111.11% over the past year.
Looking at the last year, CDXC shows a quite strong growth in Revenue. The Revenue has grown by 9.94% in the last year.
CDXC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Sales Q2Q%31.21%
3.2 Future
The Earnings Per Share is expected to grow by 64.82% on average over the next years. This is a very strong growth
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.67% yearly.
EPS Next Y158.29%
EPS Next 2Y93.61%
EPS Next 3Y64.82%
EPS Next 5YN/A
Revenue Next Year16.58%
Revenue Next 2Y18.63%
Revenue Next 3Y17.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 561.00, CDXC can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
CDXC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.55.
A Price/Forward Earnings ratio of 45.83 indicates a quite expensive valuation of CDXC.
CDXC's Price/Forward Earnings is on the same level as the industry average.
CDXC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 561 | ||
| Fwd PE | 45.83 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CDXC.
The rest of the industry has a similar Price/Free Cash Flow ratio as CDXC.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 105.51 | ||
| EV/EBITDA | 307.18 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDXC does not grow enough to justify the current Price/Earnings ratio.
CDXC's earnings are expected to grow with 64.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.54
PEG (5Y)N/A
EPS Next 2Y93.61%
EPS Next 3Y64.82%
5. Dividend
5.1 Amount
CDXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHROMADEX CORP
NASDAQ:CDXC (12/26/2024, 8:02:46 PM)
After market: 5.78 +0.17 (+3.03%)5.61
+0.17 (+3.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.56%
Inst Owner Change8.52%
Ins OwnersN/A
Ins Owner Change0.08%
Market Cap428.49M
Analysts84
Price Target7.85 (39.93%)
Short Float %4.04%
Short Ratio1.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)294.41%
Min EPS beat(2)100%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)182.5%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)109.88%
EPS beat(12)10
Avg EPS beat(12)76.36%
EPS beat(16)11
Avg EPS beat(16)52.63%
Revenue beat(2)1
Avg Revenue beat(2)0.6%
Min Revenue beat(2)-4.88%
Max Revenue beat(2)6.07%
Revenue beat(4)1
Avg Revenue beat(4)-2.29%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.07%
Revenue beat(8)3
Avg Revenue beat(8)0.11%
Revenue beat(12)3
Avg Revenue beat(12)-2.47%
Revenue beat(16)4
Avg Revenue beat(16)-2.8%
PT rev (1m)15.36%
PT rev (3m)15.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50.04%
EPS NY rev (1m)0%
EPS NY rev (3m)300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 561 | ||
| Fwd PE | 45.83 | ||
| P/S | 4.67 | ||
| P/FCF | 105.51 | ||
| P/OCF | 102.68 | ||
| P/B | 12.47 | ||
| P/tB | 12.61 | ||
| EV/EBITDA | 307.18 |
EPS(TTM)0.01
EY0.18%
EPS(NY)0.12
Fwd EY2.18%
FCF(TTM)0.05
FCFY0.95%
OCF(TTM)0.05
OCFY0.97%
SpS1.2
BVpS0.45
TBVpS0.44
PEG (NY)3.54
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROCE | 1.15% | ||
| ROIC | 0.91% | ||
| ROICexc | 5.37% | ||
| ROICexgc | 5.71% | ||
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% | ||
| FCFM | 4.43% |
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%
F-Score8
Asset Turnover1.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 13.29% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 323.49% | ||
| Profit Quality | 273.47% | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z | 9.3 |
F-Score8
WACC11.34%
ROIC/WACC0.08
Cap/Depr(3y)27.38%
Cap/Depr(5y)33.8%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y158.29%
EPS Next 2Y93.61%
EPS Next 3Y64.82%
EPS Next 5YN/A
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Sales Q2Q%31.21%
Revenue Next Year16.58%
Revenue Next 2Y18.63%
Revenue Next 3Y17.67%
Revenue Next 5YN/A
EBIT growth 1Y106.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year201.26%
EBIT Next 3Y68.25%
EBIT Next 5YN/A
FCF growth 1Y120.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y121.17%
OCF growth 3YN/A
OCF growth 5YN/A